SCHEMBL19737490

SCHEMBL19737490

O=C1C=Cc2c(c(-c3ccccc3)cn2S(=O)(=O)c2ccccc2)C1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ELAVL1 Q15717 7/20 1.00
▸ HTR6 P50406 7/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ CA12 O43570 1/20 0.42
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ CA9 Q16790 1/20 0.42
▸ PARL Q9H300 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.36
▸ MAPT P10636 1/20 0.36
▸ HPGD P15428 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dimethylamine SCHEMBL21222569 0.95 ELAVL1 (0.90) ELAVL1HTR6L3MBTL1CA12CA1
SCHEMBL22130714 0.91 ELAVL1 (0.83) ELAVL1HTR6L3MBTL1CA12CA1
SCHEMBL19737425 0.91 ELAVL1 (0.83) ELAVL1HTR6L3MBTL1CA12CA1
SCHEMBL22130634 0.91 ELAVL1 (0.83) ELAVL1HTR6L3MBTL1CA12CA1
SCHEMBL21222486 0.91 ELAVL1 (1.00) ELAVL1HTR6L3MBTL1CA12CA1
SCHEMBL22130693 0.90 ELAVL1 (0.81) ELAVL1HTR6L3MBTL1CA12CA1
SCHEMBL22130697 0.89 ELAVL1 (0.79) ELAVL1HTR6L3MBTL1CA12CA1
SCHEMBL22130694 0.89 ELAVL1 (0.79) ELAVL1HTR6L3MBTL1CA12CA1
SCHEMBL22130632 0.88 ELAVL1 (0.77) ELAVL1HTR6L3MBTL1CA12CA1
SCHEMBL19737482 0.88 ELAVL1 (0.77) ELAVL1HTR6L3MBTL1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113248419-A Synthesis method of novel HuR inhibitor 1-benzenesulfonyl-3-phenylindole-4, 5-dione 云南中医药大学 2021-08-13 — — CN claimed
CN-113248419-A Synthesis method of novel HuR inhibitor 1-benzenesulfonyl-3-phenylindole-4, 5-dione 云南中医药大学 2021-08-13 — — CN disclosed
CN-113248419-A Synthesis method of novel HuR inhibitor 1-benzenesulfonyl-3-phenylindole-4, 5-dione 云南中医药大学 2021-08-13 — — CN disclosed
US-10689342-B2 Aza-tanshinone derivatives, process for their preparation and their use in therapy UNIVERSITA' DEGLI STUDI DI TRENTO (IT) 2020-06-23 — — US disclosed
US-10689342-B2 Aza-tanshinone derivatives, process for their preparation and their use in therapy UNIVERSITA' DEGLI STUDI DI TRENTO (IT) 2020-06-23 — — US disclosed
US-20190241516-A1 AZA-TANSHINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THERAPY UNIVERSITA' DEGLI STUDI DI TRENTO (IT) 2019-08-08 — — US disclosed
US-20190241516-A1 AZA-TANSHINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THERAPY UNIVERSITA' DEGLI STUDI DI TRENTO (IT) 2019-08-08 — — US disclosed
WO-2017216732-A1 AZA-TANSHINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THERAPY UNIVERSITA' DEGLI STUDI DI MILANO (IT) 2017-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190241516-A1 AZA-TANSHINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THERAPY AZI2, TPMT, TYMS ELAVL1 2765/4885HTR6 1922/4885L3MBTL1 4885/4885
US-10689342-B2 Aza-tanshinone derivatives, process for their preparation and their use in therapy AZI2, TPMT, TYMS ELAVL1 2765/4885HTR6 1922/4885L3MBTL1 4885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback